Apertura Gene Therapy Named to Consortium Receiving Funding from the Advanced Research Projects Agency for Health (ARPA-H) THRIVE Program to Develop Gene Therapies for Rare Childhood Diseases

PartnershipTfR1 CapX™Positive

AI Analysis

Summary

Apertura Gene Therapy was selected for an ARPA-H THRIVE Program-funded consortium led by the Broad Institute to develop gene therapies for rare childhood diseases using its novel CNS-targeted AAV capsid technology for base and prime editing applications.

Outcome Details

Apertura Gene Therapy named to consortium receiving ARPA-H THRIVE Program funding for development of gene therapies using CNS-targeted AAV capsid

Importance:6/10

Sentiment:

0.70

gene_therapyrare_diseaseAAV_capsidCNS_targetingbase_editingprime_editinggovernment_fundingARPA-H

Related Companies

$GBIO $HIT

Read the original article

Published by PR Newswire Biotech on July 23, 2026 4:00 PM

Read Original